|
| Preliminary study on clinical efficacy of “Qingfei Paidu Granule” in treating coronavirus disease 2019 |
| Hits 4619 Download times 1025 Received:June 11, 2020 |
| View Full Text View/Add Comment Download reader |
| DOI
10.11656/j.issn.1672-1519.2020.09.09 |
| Key Words
coronavirus disease 2019;Qingfei Paidu Granule;clinical research |
| Author Name | Affiliation | E-mail | | HU Gangming | Department of Traditional Chinese Medicine, Hanchuan City People's Hospital, Renmin Hospital of Wuhan University Hanchuan Hospital, Hanchuan 431600, China | | | HE Chaoxiong | Department of Traditional Chinese Medicine, Hanchuan City People's Hospital, Renmin Hospital of Wuhan University Hanchuan Hospital, Hanchuan 431600, China | 2825475854@qq.com | | SUN Qiuling | Department of Traditional Chinese Medicine, Hanchuan City People's Hospital, Renmin Hospital of Wuhan University Hanchuan Hospital, Hanchuan 431600, China | | | WAN Binbin | Department of Rheumatology and Immunology, Wuhan First Hospital, Wuhan 430022, China | | | LI Yubin | Department of General Surgery, Hubei 672 Orthopaedics Hospital of Integrated Chinese & Western Medicine, Wuhan 430079, China | | | GAO Jieyuan | Department of Traditional Chinese Medicine, Hanchuan City People's Hospital, Renmin Hospital of Wuhan University Hanchuan Hospital, Hanchuan 431600, China | | | WU Zhenggang | Department of Traditional Chinese Medicine, Hanchuan City People's Hospital, Renmin Hospital of Wuhan University Hanchuan Hospital, Hanchuan 431600, China | | | ZENG Jinjun | Department of Traditional Chinese Medicine, Hanchuan City People's Hospital, Renmin Hospital of Wuhan University Hanchuan Hospital, Hanchuan 431600, China | |
|
| Abstract
|
| [Objective] To observe the preliminary clinical study on coronavirus disease 2019 (COVID-19) treated by Qingfei Paidu Granule (QFPDKL).[Methods] The 76 patients with COVID-19 were included in the observation and treated with QFPDKL,with 5 days as a course of treatment. After 3 courses of treatment,the changes of Traditional Chinese Medicine (TCM) syndrome scores and the improvement of laboratory related indicators were compared before and after treatment. TCM syndromes were judged by scoring method according to the severity of symptoms.[Results] Compared with before treatment,the total score of syndromes after treatment of QFPDKL for 5,10 and 15 days decreased significantly (P<0.01). The total scores of primary and secondary symptoms were significantly lower than those before treatment (P<0.01). Laboratory tests showed that compared with before treatment,lymphocyte percentage (LVMPH%) increased,alanine aminotransferase (ALT),D-Dimer,C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) decreased,and gradually returned to normal,the difference was statistically significant (P<0.01). The negative rate of nucleic acid and the improvement rate of lung computed tomography (CT) were 92.10%. After 5 days of treatment,18 cases were basically cured,26 cases were markedly effective,and the total effective rate was 57.89%. After 10 days of treatment,32 cases were basically cured,27 cases were markedly effective,and the total effective rate was 77.63%. After 15 days of treatment,50 cases were basically cured,17 cases were markedly effective and the total effective rate was 88.16%.[Conclusion] QFPDKL can effectively control patients' clinical symptoms and improve laboratory abnormal detection indicators,and can be well used in the treatment of COVID-19. Its clinical effect is remarkable,with few adverse reactions,and it is worth popularizing and using. |
|
|
|
|
|
|
|
